No abstract available
MeSH terms
-
Antidepressive Agents, Second-Generation / pharmacokinetics*
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Agents, Hormonal / pharmacokinetics*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / metabolism*
-
Breast Neoplasms / pathology
-
Cyclohexanols / pharmacokinetics
-
Cytochrome P-450 CYP2D6 / metabolism*
-
Estrogen Receptor Modulators / adverse effects
-
Estrogen Receptor Modulators / pharmacokinetics*
-
Estrogen Replacement Therapy / adverse effects
-
Female
-
Fluoxetine / pharmacokinetics
-
Hot Flashes / chemically induced
-
Humans
-
Hydroxylation
-
Paroxetine / pharmacology
-
Randomized Controlled Trials as Topic
-
Selective Estrogen Receptor Modulators / adverse effects
-
Selective Estrogen Receptor Modulators / pharmacokinetics*
-
Tamoxifen / adverse effects
-
Tamoxifen / analogs & derivatives*
-
Tamoxifen / metabolism*
-
Tamoxifen / pharmacokinetics*
-
Venlafaxine Hydrochloride
Substances
-
Antidepressive Agents, Second-Generation
-
Antineoplastic Agents, Hormonal
-
Cyclohexanols
-
Estrogen Receptor Modulators
-
Selective Estrogen Receptor Modulators
-
Fluoxetine
-
Tamoxifen
-
afimoxifene
-
Paroxetine
-
Venlafaxine Hydrochloride
-
Cytochrome P-450 CYP2D6
-
N-desmethyltamoxifen